Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Cancer Research Année : 2022

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Louis Garnier
Chrystelle Vidal
  • Fonction : Auteur
Elisabeth Cohen-Jonathan Moyal
  • Fonction : Auteur
Apolline Djelad
  • Fonction : Auteur
Charlotte Bronnimann
  • Fonction : Auteur
Lien Bekaert
  • Fonction : Auteur
Luc Taillandier
  • Fonction : Auteur
Jean-Sébastien Frenel
  • Fonction : Auteur
Olivier Langlois
  • Fonction : Auteur
Philippe Colin
  • Fonction : Auteur
Philippe Menei
  • Fonction : Auteur
Frédéric Dhermain
  • Fonction : Auteur
Catherine Carpentier
  • Fonction : Auteur
Aurélie Gerazime
  • Fonction : Auteur
Elsa Curtit
  • Fonction : Auteur
Caroline Dehais
  • Fonction : Auteur
François Ducray
  • Fonction : Auteur
  • PersonId : 919913

Résumé

In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
Fichier principal
Vignette du fichier
oyac023.pdf (3.63 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-03976603 , version 1 (07-02-2023)

Licence

Identifiants

Citer

Louis Garnier, Chrystelle Vidal, Olivier Chinot, Elisabeth Cohen-Jonathan Moyal, Apolline Djelad, et al.. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28 (12), pp.2527-2535. ⟨10.1093/oncolo/oyac023⟩. ⟨hal-03976603⟩
30 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More